Q4 2023 · 13F-HR
Finepoint Capital LPholdings as filed
Filed 2024-02-13 · accession 0000904454-24-000134
$317.0M
Reported value
27
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 23282W605 | CYTK | CYTOKINETICS INC | $36.0M | 11.4% | 431,693 | Common | SOLE |
| 848577102 | SAVEEUR | SPIRIT AIRLINES INC | $27.9M | 8.79% | 1,700,000 | CALL | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $24.1M | 7.60% | 769,653 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $21.1M | 6.67% | 1,489,025 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $20.8M | 6.55% | 504,700 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $20.6M | 6.51% | 163,772 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $20.3M | 6.41% | 556,928 | Common | SOLE |
| 43734R111 | — | HOME PLATE ACQUISITION CORP | $20.0M | 6.31% | 331,416 | Common | SOLE |
| 36315X101 | LKFT | GALAPAGOS NV | $18.6M | 5.88% | 458,659 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $17.7M | 5.58% | 617,100 | Common | SOLE |
| 530307305 | LBRDK | LIBERTY BROADBAND CORP | $14.9M | 4.69% | 184,460 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $14.5M | 4.58% | 1,317,870 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HOLDING INC | $14.3M | 4.53% | 496,856 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $14.0M | 4.42% | 145,357 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $12.9M | 4.07% | 1,435,321 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $12.7M | 4.00% | 349,300 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $5.9M | 1.86% | 961,251 | Common | SOLE |
| 320703101 | — | CALIDI BIOTHERAPEUTICS INC | $188,750 | 0.06% | 125,000 | Common | SOLE |
| 17144M110 | — | CHURCHILL CAPITAL CORP VII | $71,295 | 0.02% | 548,000 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $62,740 | 0.02% | 895,000 | Common | SOLE |
| 20607U116 | CNDAW | CONCORD ACQUISITION CORP II | $53,083 | 0.02% | 408,333 | Common | SOLE |
| 320703119 | CLDWW | CALIDI BIOTHERAPEUTICS INC | $32,760 | 0.01% | 655,200 | Common | SOLE |
| G7641C114 | — | ROSS ACQUISITION CORP II | $24,621 | 0.01% | 439,666 | Common | SOLE |
| G2476C123 | CDAWF | COMPASS DIGITAL ACQUISITION CORP | $22,259 | 0.01% | 459,906 | Common | SOLE |
| 56608A113 | — | MARBLEGATE ACQUISITION CORP | $22,050 | 0.01% | 735,000 | Common | SOLE |
| G63836111 | IVCPW | SWIFTMERGE ACQUISITION CORP | $20,090 | 0.01% | 490,000 | Common | SOLE |
| G9845F117 | LSBWF | YS BIOPHARMA CO LTD | $13,279 | 0.00% | 489,999 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.